sonyaglave282d76 @sonyaglave282d76: "𝘽𝙧𝙞𝙨𝙩𝙤𝙡 𝙈𝙮𝙚𝙧𝙨 𝙎𝙦𝙪𝙞𝙗𝙗: 𝘼 𝘾𝙚𝙣𝙩𝙪𝙧𝙮..."

Bulgaria

𝘽𝙧𝙞𝙨𝙩𝙤𝙡 𝙈𝙮𝙚𝙧𝙨 𝙎𝙦𝙪𝙞𝙗𝙗: 𝘼 𝘾𝙚𝙣𝙩𝙪𝙧𝙮 𝙤𝙛 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 𝙖𝙣𝙙 𝙄𝙣𝙫𝙚𝙨𝙩𝙢𝙚𝙣𝙩 𝙋𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 With a history spanning over 100 years, Bristol Myers Squibb remains a major player in the pharmaceutical sector. Founded in 1887, the company has a strong track record of developing breakthrough medicines for serious diseases, particularly in oncology, hematology, cardiovascular, immunology, and fibrosis. 𝙍𝙚𝙘𝙚𝙣𝙩 𝙎𝙩𝙤𝙘𝙠 𝙋𝙪𝙡𝙡𝙗𝙖𝙘𝙠 𝘾𝙧𝙚𝙖𝙩𝙚𝙨 𝙄𝙣𝙫𝙚𝙨𝙩𝙢𝙚𝙣𝙩 𝙊𝙥𝙥𝙤𝙧𝙩𝙪𝙣𝙞𝙩𝙮 Recently, $BMY (Bristol-Myers Squibb Co) has experienced a notable pullback in its stock price, hitting lows of $41—levels not seen since 2013. This price point represents strong technical resistance, creating an attractive opportunity for long-term investors. The stock is currently trading with a low Price-to-Earnings (P/E) ratio (2.2) and offers a generous dividend payout, making it an appealing addition to any investment portfolio. 𝙎𝙞𝙜𝙣𝙨 𝙤𝙛 𝙋𝙧𝙤𝙛𝙞𝙩𝙖𝙗𝙞𝙡𝙞𝙩𝙮 𝙤𝙣 𝙩𝙝𝙚 𝙃𝙤𝙧𝙞𝙯𝙤𝙣 Despite recent challenges, including patent expirations and high R&D costs, $BMY 's latest quarterly earnings show promising signs of a return to profitability—beating second-quarter earnings expectations on both the top and bottom lines and raising its full-year guidance. 𝙀𝙡𝙞𝙦𝙪𝙞𝙨 𝙄𝙢𝙥𝙖𝙘𝙩: 𝙈𝙖𝙣𝙖𝙜𝙚𝙖𝙗𝙡𝙚 𝙖𝙣𝙙 𝙋𝙧𝙤𝙛𝙞𝙩𝙖𝙗𝙡𝙚 The impact of the IRA on Bristol Myers Squibb’s Eliquis appears to be manageable. The blood thinner generated $3.4 billion in the second quarter, reflecting a 7% increase from the previous year. Eliquis contributed $12.2 billion, nearly 25% of BMS’s total revenue of $45 billion for 2023. 𝘼 𝘾𝙤𝙢𝙥𝙚𝙡𝙡𝙞𝙣𝙜 𝘾𝙝𝙤𝙞𝙘𝙚 𝙛𝙤𝙧 𝙇𝙤𝙣𝙜-𝙏𝙚𝙧𝙢 𝙂𝙧𝙤𝙬𝙩𝙝 For those seeking long-term growth and stability, $BMY offers an excellent investment opportunity. The current market conditions, even after the recent rise in the stock price, coupled with the company’s solid dividend and low P/E ratio, make it a compelling choice for investors. 𝗜𝗻 𝗺𝘆 𝗼𝗽𝗶𝗻𝗶𝗼𝗻, $BMY 𝗶𝘀 𝗮𝘁 𝗹𝗲𝗮𝘀𝘁 𝟲𝟬% 𝘂𝗻𝗱𝗲𝗿𝘃𝗮𝗹𝘂𝗲𝗱 𝗮𝗻𝗱 𝗵𝗮𝘀 𝗴𝗿𝗲𝗮𝘁 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝗴𝗿𝗼𝘄𝘁𝗵. *𝗔𝘀 𝗼𝗳 𝘁𝗵𝗲 𝘁𝗶𝗺𝗲 𝗼𝗳 𝘄𝗿𝗶𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗮𝗿𝘁𝗶𝗰𝗹𝗲, 𝗺𝘆 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗵𝗮𝘀 𝘆𝗶𝗲𝗹𝗱𝗲𝗱 𝗮 𝟮𝟬% 𝗿𝗲𝘁𝘂𝗿𝗻. $BMY $PFE (Pfizer) $AMGN (Amgen Inc) $ABBV (AbbVie Inc) $VRTX (Vertex Pharmaceuticals Incorporated) $BNTX (BioNTech SE-ADR) $JNJ (Johnson & Johnson) $MAERSKB.CO (A P Moller Maersk)